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ABSTRACT 
Molecular defects in the lipoprotein lipase (LPL) gene account for a significant 
proportion of the occurrence of the massive hypertriglyceridemia and other clinical 
manifestations of the chylomicronemia syndrome. Furthermore, some published reports 
suggest that the heterozygous state for LPL deficiency leads to a reduced capacity to 
clear triglyceride-rich lipoproteins from plasma; when this clearance is saturated through 
dietary or hormonal factors, moderate hypertriglyceridemia may be observed. The LPL 
gene of four hypertriglyceridemic subjects was examined for the presence of molecular 
variants. In one subject with the classical presentation of the chylomicronemia syndrome 
and documented deficiency of LPL activity in postheparin plasma, we have identified a 
mutation leading to the substitution of glutamic acid for glycine at residue 195 of the 
mature enzyme. The patient was homozygous for this mutation. By in vitro mutagenesis 
and transient expression in cultured mammalian cells, it was shown that the protein 
encoded by this mutated sequence lacked catalytic activity, and data on the homologous 
enzyme pancreatic lipase indicate that this mutation occurred within the catalytic domain 
of the enzyme. By contrast, we identified two other mutations in two of the three other 
hypertriglyceridemic subjects with moderate hypertriglyceridelnia that did not appear of 
functional significance. Therefore, we have found no evidence of a role of molecular 
defects of LPL in these milder cases. 
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INTRODUCTION 
Lipid Transport in Plasma 
Long-chain fatty acids of intestinal or hepatic origin transit in plasma after 
esterification with glycerol to form triacylglycerols. The transport of this hydrophobic 
material in an aqueous environment is achieved by associating the rather insoluble lipids 
with more polar ones, such as phospholipids, and combining them with cholesterol and 
protein to form hydrophilic lipoprotein particles. Synthesized by the intestine and the 
liver, lipoproteins undergo a series of catabolic steps before they are cleared by specific 
cellular receptors (Havel and Kane, 1989). Heterogeneity in size and density has led to 
the definition of discrete classes of lipoproteins, as summarized in Table 1. The 
characterization of their tissue of origin, lipid and protein composition, and metabolic 
fate has led to the model of plasma lipid transport and metabolism depicted in Figure 1. 
Disorders of Lipid Metabolism 
A variety of pathological states are associated with either abnormal concentration 
or altered composition of some lipoproteins, referred to as hypolipidemias, 
hyperlipidemias and dyslipidemias. A classification of the hyperlipidemias (Table 2) has 
been introduced by Fredrikson and Levy (1967). Although this classification was based 
on an analysis of observed lipid profiles within families with several hyperlipidemic 
Table 1. Physical and Chemical Features of Human Plasma Lipoprotein Classes. 
Class Density EleCtrophoretic Diameter Surface Components Core L~idS 
g/ml mobility nm Ct PI ApoLp Tg E 
Chylomicrons 0.93 Remains at Origin 75-1200 2 7 2 86 3 
VLDL 0.93-1.006 Pre-P-Lipoproteins 30-80 7 18 8 55 12 
IDL 1.006-1.019 Slovv~L~proteins 25-35 9 19 19 23 29 
LDL 1.019-1.063 p-Lipoproteins 18-25 8 22 22 6 42 
HDL2 1.063-1.125 p-Lipoproteins 9-12 5 33 40 5 17 
HDL3 1.125-1.210 p-Lipoproteins 5-9 4 35 55 3 13 
Legend: Surface Components and Core Lipids gives as % of Dry Mass. 
Abbreviations: VLDL, Very Lovv Density L~protein; IDL, Intennediate Density ~proteins; LDL, Low Density Lipoproteins; 
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Both the exogenous and endogenous cycles begin with the secretion of triglyceride-rich particles (chylomicrons and VLDL) 
that are converted to cholesteryl ester-rich particles (remnants, IDL, and LDL) through interaction with LPL. Abbreviations: 
LPL, lipoprotein lipase; VLDL, very low density lipoproteins; IDL, intermediate density lipoproteins; LDL, low density 
lipoproteins; HDL, high density lipoproteins; LCAT, lecithin cholesterol acyltransferase. 
w 
Table 2. Classification of Hyperlipoproteinemias. 
Li12012roteins LiQids 
Type Chy VLDL LDL CH TO 
1 +++ Nor t N t ttt 
2a 0 N tt tt N 
2b 0 t t t t 
3 0 tt Nor ..1- tt tt 
(abnonnal) 
4 0 tt N N tt 
5 ++ tt ' N t ttt 
Note: Chy, chylomicrons; VLDL, very low density lipoproteins; 
LDL, low density lipoproteins; CH, cholesterol; 
TO, triglycerides; N, normal 
4 
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subjects, it does not correspond to well defined genetic entities. Furthennore, clustering 
of different types of hyperlipidemias within families is rather common. This is 
particularly the case for the hyperlipidemias characterized by increased plasma 
concentration of triglycerides, where Type I, Type V, and Type IV profiles are often seen 
among close relatives. 
High plasma concentrations of triglycerides may result from increased synthesis, 
impaired plasma catabolism, or decreased clearance of triglyceride-rich lipoproteins. By 
hydrolyzing triglycerides from chylomicrons and very low density lipoproteins (VLDL), 
the enzyme lipoprotein lipase plays a central role in their remodeling and eventual 
clearance. This graduate research work has consisted of the molecular analysis of the 
lipoprotein lipase gene in four hypertriglyceridemic subjects. Pertinent infonnation 
regarding the biochemistry and gene structure of LPL, LPL deficiency states, and outline 
the rationale of the study will be sumarized. 
Lipoprotein Lipase : General Properties 
Lipoprotein lipase (LPL; triacylglyceroprotein acylhydrolase, EC 3.1.1.34) is an 
extracellular enzyme synthesized by a variety of parenchymal cells including adipocytes, 
skeletal and cardiac muscle cells, the mammary gland and activated macrophages. After 
secretion from such producing cells, the enzyme diffuses through the vascular tree and 
becomes anchored to the surface of the capillary endothelium of extrahepatic tissues by 
an ionic interaction with the glycosaminoglycan heparan sulfate. The enzyme, which 
requires the specific cofactor apolipoprotein C-II for efficient catalytic activity, 
hydrolyses triacylglycerols by binding to the surface of chylomicrons and very low 
6 
density lipoproteins (VLDL), thereby releasing free fatty acids for uptake into the tissues 
where they can either be used immediately as fuel or reesterified for storage. General 
properties of the enzyme are presented in Figure 2. Thus the enzyme plays a key role 
in the metabolism of large triglyceride-rich lipoproteins to smaller particles, and 
detennines the distribution of fatty acid energy among various tissues. General reviews 
summarize a vast literature on the biochemistry of this enzyme, such as Smith and 
Pownall (1984), Garfmkel and Schotz (1987), or Olivecrona and Bengtsson-Olivecrona, 
(1987). 
Hormonal regulation of LPL has mainly been studied in adipose tissue or isolated 
adipocytes. Stimulation of adipose tissue enzyme activity has been demonstrated by 
insulin, glucocorticoids, adenosine analogues, gastrin and pancreozymin. Inhibitory 
effects on LPL activity in adipose tissue have been observed with catecholamines, 
dibutyryl cAMP and estrogens. Aspects of hormonal regulation of LPL activity are 
reviewed in Weinberg (1987). 
Lipoprotein Lipase: Functional Domains 
Similar to other lipases, it is assumed that LPL requires intact catalytic as well 
as interfacial lipid binding sites in order to hydrolyze lipid emulsions and lipoprotein 
particles. Although LPL readily binds to lipid-water interfaces, the enzyme also requires 
a protein cofactor, apolipoprotein C-II, to become fully active. The cofactor requirement 
of LPL disappears when soluble substrates are hydrolyzed. The striking homology that 
has been demonstrated between LPL, hepatic triglyceride lipase, and pancreatic lipase, 






native 475 aa, mature 448 aa, 55 kDa, 8% carbohydrates 
glycosylated at Asn 43 and Asn 359 
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8-9 
Activated by Apo C-II 
Figure 2. Physical properties of lipoprotein lipase. 
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may actually hint at the structure of some of the functional domains of LPL. In these 
enzymes there is a large region of homology, from residue 105 to residue 209 in human 
LPL. This region includes a putative sequence for interfacial lipid binding (human 
residues 126-135). References can be found in the general reviews quoted in the previous 
section. 
Some work on bovine LPL and canine pancreatic lipase suggested that the active 
serine of human LPL may be located at residue 132. Recently, the three-dimensional 
structure of the human pancreatic lipase gene has been solved (Winkler et aI., 1990), 
confirming that the catalytic site of pancreatic lipase (PL) consists of the Ser-Asp-His 
catalytic triad commonly found in serine proteases. The specificity of the enzyme for 
lipid substrates appears to be related to the buried localization of the active serine in a 
pocket with a high density of hydrophobic residues. The homology of human LPL and 
PL becomes manifest when both sequences are optimally aligned (Figure 3). 
Other functional domains of LPL, such as the cofactor binding site and the 
heparin-binding site, remain to be identified. Furthermore, although the noncovalent 
homodimer structure of the active enzyme has been demonstrated, the sequence elements 
involved in this interaction are unknown. Consequently, the identification of molecular 
variants of LPL may provide an opportunity to identify such functional domains. 
Lipoprotein Lipase: Gene Structure 
The human LPL complementary DNA (cDNA) has been cloned from adipose 
tissue (Wion et aI, 1987). It encodes a protein of 475 an1ino acids including an apparent 
HUMAN LIPOPROTEIN (LPL) AND PANCREATIC (PL) LIPASES 
70 80 90 100 110 
1 YESWVPKLVAALYKREPDSNVIVVDWLSRAQEHYPVSAGYTKLVGQDVARFINWMEEE 
I I I I I I I III I II II I 
2 EENWLANVCKNLFKVE-SVNClCVDWKGGSRTGYTQASQNIRlVGAEVAYFVEFLQSA 
90 100 110 120 130 -
120 130 140 150 160 170 
FNYPLDNVHLLGYS LGAHAAG lAGS LTNKKVNRlTGLDPAGPNFEYAEAPSRLS PDDA 
I I III I 11111111 II" 11111111 I I II I II 
FGYSPSNVHVlGHSLGAHAAGEAGRRTNGTIGRlTGLDPAEPCFQGTPELVRLDPSDA 
140 150 * 160 170 * 180 190 
180 190 200 210 220 230 
DFVDVLHT-FTRGSPGRSlGlQKPVGHVDlYPNGGTFQPGC--NlGEAlRVlAERGLG 
I1II II I I III I I11I III II I I I 
KFVDVlHTDGAPlVPNLGFGMSQVVGHLDFFPNGGVEMPGCKKNlLSQlVDlDGlWEG 
200 210 220 230 240 250 
240 250 260 
DVDQLVKCSHERSlHLFlDSLLNEENPSKAYRCS 265 
I I I II II I I 
TRD-FAACNHLRSYKYYTDSlVNPDGFAGFPCAS 287 










PL LPL . 
237 - 261 216 - 239 
Figure 3. The homology of human lipoprotein lipase and 
pancreatic lipase: central region of homology. 
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signal peptide of 27 amino acids and three potential asparagine-linked glycosylation sites. 
LPL mRNA was detected in adipose tissue, adrenals, kidney and intestine, but not in 
liver, the Hep02 hepatoma cell line or white blood cells. Two hybridizing species of 
3350 and 3750 nucleotides seem to represent LPL message terminating with roughly 
equal frequency at polyadenylation sites separated by 395 nucleotides. LPL shows 
extreme conservation across species, with 7% and 6% amino acid differences between 
human and murine or bovine proteins respectively (Datta et aI., 1988). Furthermore, it 
displays strong evolutionary relationships with other lipolytic enzymes such as hepatic 
lipase and pancreatic lipase. The LPL gene maps to human chromosome 8, and its 
genomic structure has been determined (Deeb and Peng, 1989). It spans 30 kilobases, and 
includes 10 exons. Exons 1 to 9 range in size from 106 to 276 bp; exon 10 encodes the 
entire 3' noncoding sequence of the gene and is 1948 bp in length (Figure 4). 
Lipoprotein Lipase Deficiency 
Familial lipoprotein lipase deficiency is a rare autosomal recessive condition 
characterized by massive chylomicronemia, with triglyceride (TO) concentrations 
typically ranging from 1500 to 4500 mg/dl, normal or moderately elevated VLDL 
concentrations, and markedly depressed concentrations of both LDL and HDL (Nikkila, 
1983; Brunzell, 1989). It is usually detected in infancy or childhood on the basis of 
repeated episodes of abdominal pain, recurrent acute pancreatitis, and eruptive 
xanthomas, but it can also remain asymptomatic and be detected through routine blood 




























2 3 4 5 6 7 
I I I I II I / / / 1/ / r , \ II I 
I I I I I, I I 1\ /1 / 
'/ / / 1// I I , " I 
I I I 'I/ \ / I I I ' 1 '/ ", I I I / I / II I \ ' I I 
I' I I ' '/ f I I J 
I I I /' I I ", I I I 
I I I 1/1/ /1 \ I I I 
I I I I I II ' , \ , I I 
1 I I I I '/ " \ I I I 
I I I /, /1 II , I I I 
I I / '.1 1/ II \ I I I 
I I I II /1 " 'I I I 
I , I I I 1/ II \ / I I 
I I I / I /1 ' , l I I , 
I I I 1/ II II \ / II 
/ I I /1 /1 I' , I ,I 
I I I II I . r' \ I 
.1 "' I \, 
Structure of the human LPL gene. 
8 9 
1\ , 
I \ I 
t I , I 
, I \ , 
\ " , \ I \ , 
\ " , \ I \ , 
'I' , 
'I \ , 
I I , , 
'I \ , 
II , , 
, I \ I 
" " \I \ I II , , 
. \ , 






The length of LPL gene is approximately 30 kb (the top portion of the figure). The 10 exons are represented by the filled 
boxes. Solid portions of exons represent none-coding sequences. The cDNA is interrupted by 9 introns giving rise to 10 
exons. Exons 1-9 are of average size (105-276 bp) whereas exon 10 ,which codes for all of the 3' untranslated region of the 




establishes the diagnosis. A recent study of LPL-deficient, unrelated probands revealed 
a major genomic rearrangement in 4 of 19 alleles (Langlois et aI., 1989) resulting from 
an internal duplication disrupting the normal structure of the gene (Devlin et aI., 1990). 
Other mutations of the gene, including several amino acid substitutions, have been 
reported (Emi et aI., 1990; Hata et al., 1990; Beg et al., 1990; Dichek et al., 1991). Less 
often, a similar syndrome can be ascribed to functional deficiency or absence of the LPL 
cofactor, apo C-II, which can be diagnosed by assaying cofactor activity of the patient's 
plasma (Nikkila, 1983; Brunzell, 1989). 
H ypertri glyceride n1ia 
The heterozygous state for LPL deficiency (LP~) remains poorly characterized. 
Obligate heterozygotes are either normal or exhibit mild hyperlipidemia, and multiple 
lipoprotein phenotypes have been observed in some pedigrees. Measuring both mass and 
activity of LPL, Babirak et aI. (1989) suggested that Hypertriglyceridemia in relatives of 
LPL deficient probands, possibly of the type seen in familial combined hyperlipidemia 
(HLP), segregated with LP~; only about half of the subjects thus classified as 
heterozygotes exhibited HTG. Identifying carriers at the molecular level in a large 
pedigree, Wilson et al. were able to characterize the phenotypic expression of LP~ 
(Wilson et aI, 1990), with delayed expression of HTG, high VLDL cholesterol, 
subnormal LDL cholesterol and reduced HDL cholesterol concentrations. 
Familial forms of HTG may result from LP~, at least in some families. Four 
familial lipid disorders featuring HTG have been defined (Havel and Kane, 1989): (1) 
in familial hypertriglyceridemia (FHTG), affected relatives have elevated plasma VLDL 
13 
but normal or low LDL concentrations (type IV); (2) in primary type V HLP, 
chylomicronemia and/or elevated VLDL are observed in family members (types V and 
IV); (3) in familial combined HLP (FCHL), multiple lipoprotein phenotypes are observed 
among relatives, including isolated elevation of VLDL (type IV), isolated elevation of 
LDL cholesterol (type IIa), or elevation of both (type IIb); (4) in type III HLP, a rare 
condition associated with premature atherosclerosis and usually homozygosity for the E2 
electrophoretic variant of apolipoprotein E, high cholesterol and triglyceride 
concentrations result from the accumulation of abnormal B-VLDL particles. Although 
this purely phenotypic classification is unlikely to be of much etiological significance, 
it has served as a basis for clinical investigations over the past two decades. 
The mechanisms underlying increased plasma VLDL remain poorly understood. 
Extrinsic factors such as obesity, diabetes, excessive alcohol intake, or medication with 
exogenous steroids contribute to the etiology of HTG. Some metabolic investigations in 
various HTG subjects (type IV or type IIb) would support a predominant role for VLDL 
overproduction, while others suggest that defective VLDL removal is of greater 
significance (Grundy, 1984; Grundy and Vega, 1988). Compositional differences of 
VLDL particles have been reported between type IV and type lIb pro bands. In type V 
subjects, turnover studies best support a combination of both overproduction and 
impaired clearance of VLDL. Assessment of the published evidence is further 
complicated by differences in patient selection and experimental procedures. At present, 
it is reasonable to conclude that both factors are at play to varying degrees in HTG 
patients. Whether overproduction or decreased clearance account for familial aggregation 
can also be debated. In the only large series where kinetic parameters were investigated 
14 
among type IV relatives of FHTG or FCHL probands (Sane and Nikkila, 1987), it was 
found that reduced clearance, but not overproduction, followed a familial pattern, and 
that no particular feature of VLDL triglyceride kinetics could distinguish type IV subjects 
in FHTG from type IV subjects in FCHL. 
A common, saturable removal system for which both endogenous and exogenous 
triglycerides depend and compete was revealed by dietary manipulations in HTG subjects 
and appears related to LPL (Brunzell et ai., 1973). An inverse relationship exists between 
fasting plasma TG concentration and postheparin plasma or adipose tissue LPL activities, 
the latter being negatively correlated with obesity. The relationship between HTG and 
LPL activity is blurred by variations in assay procedures. Furthermore, measurement of 
total LPL activity does not distinguish between differences in specific activity and 
differences in total pool of the enzyme; the latter is subject to a host of hormonal 
influences (Weinberg, 1987). Consequently, LPL activity in plasma collected after an 
heparin injection cannot serve as a predictor of the heterozygous state for LPL 
deficiency. 
A combination of both overproduction and decreased clearance appears to be 
involved in most HTG subjects, and the phenotypic definition of familial syndromes must 
admit substantial etiological heterogeneity. Observations in such families, as well as on 
LP~, support a role for an inherited defect of LPL in an as yet undefined subset of 
familial HTG. Interactions with other factors, genetic or environmental, account for 
variation in phenotypic expression. This is clearly the picture emerging from studies of 
familial type V HLP (Grundy and Vega, 1988). Overproduction may result from obesity, 
alcohol, estrogen use, or diabetes, while decreased clearance may result either from down 
15 
regulation or froln inherited, partial deficiency in LPL. 
Rationale and Significance of the Present Study 
Genetics, nutrition, and metabolic or hormonal disturbances influence plasma TG 
concentrations. Mutations leading to quasi-complete deficiency lead to type I HLP in the 
homozygous state, with a prevalence in the order of 10-6• Even such patients, however, 
express type IV HTG when adhering to a stringent low fat diet (Nikkila, 1983; Brunzell, 
1989). LP4, a much more prevalent genotype, represents a latent lipolytic defect leading 
to delayed expression of HTG (type IV or type V) when triggered by nutritional, 
metabolic or hormonal factors. 
Consequently, current study has examined the hypothesis that molecular variants 
of the LPL gene may account for HTG in 4 subjects referred to us by Dr Gerald Luc, 
from the Hospital Hotel Dieu in Paris, France. In subject K2042, the quasi-absence of 
LPL activity in post-heparin plasma suggested LPL deficiency in the homozygous state. 
Other subjects examined presented plasma triglycerides in excess of 1000 mg/dl, with 
either normal or elevated VLDL cholesterol (Type IV or Type V hyperlipidemia). The 
hypothesis was that these subjects could carry mutations of the LPL gene in the 
heterozygous state. 
MATERIALS AND METHODS 
Subjects 
Four individuals with hypertriglyceridemia and one normal individual as a control 
(samples 1 to 5) were screened for the presence of molecular variants of LPL. (fable 3). 
One subject had classical symptoms of the chylomicronemia syndrome and documented 
deficiency of LPL activity in postheparin plasma. Other exhibited triglyceride levels in 
excess of 1,000 mgldl, but no underlying metabolic disorder which could account for 
hypertriglyceridemia. Blood samples collected on ACD tubes were forwarded to this 
laboratory by special courier. 
Southern Blot Analysis 
Total genomic DNA was isolated from peripheral blood by a standard method. 
For each subject, 3.6 Jlg of total genomic DNA was digested with the restriction enzyn1es 
PstI and StuI, respectively. Following 37°C overnight incubation, DNA was loaded on 
0.5% and 0.7% agarose gels, electrophoresed at 22 to 25 Volts for 16 hours, and 
transferred to nylon membranes (Bio Trace™ RP, Gelman Sciences, Ann Arbor, MI). 
Hybridization was performed with the 32p labeled cDNA clone pLPL35 as a probe for 
10 hours. The membranes were washed in 0.1 X SSC/0.1 % SDS washing solution 























* The offspring of a consanguineous marriage. 
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(Ix SSC= 0.15M NaCV15 mM Na citrate, ph 7.0) for 30 minutes at 52°C and submitted 
to autoradiography. 
Detection of Molecular Variants as Conformational Polymorphisms 
Each of the nine translated exons of the human LPL gene was enzymatically 
amplified (Mullis, et al., 1987) from genomic DNA on a Thermal Cycler (Perkin Elmer-
Cetus, Norwalk, Cf) basically following the method of Orita et al. (1989). 
Oligonucleotide sequences used as primers are shown in Table 4. The reaction mixture 
contained 5.2 pmol of each primer, 2 nmol of each dNTP, 0.1 Jlg of genomic DNA, 1 
JlCi of [a-32P]dCfP (3000Ci/mmol, 10 mCi/ml, Amershan) and 0.05 units of Tag 
polymerase (perkin Elmer-Cetus, Norwalk, Cf) in 10 JlI of amplification buffer. This 
mixture was subjected to the iterative application of 10 reaction cycles each including 
denaturation at 95°C for 1 minute, primer-annealing (at 48°C for exon 1, at 43°C for 
exons 8 and 9, and at 54°C for other exons) for 1 minute, and primer-extension at 72°C 
for 1 minute. For all exons, 20 subsequent cycles were applied with primer-annealing 
performed at 60°C. After amplification, 50 Jll of 0.1 % SDS/10 mM EDT A was added 
in the mixture. An aliquot was withdrawn and mixed with equal volume of 95% 
formamide dye, boiled for 2 minutes and applied (2 Jll/lane) to a 5% polyacrylamide gel 
containing 0.5 X TBE, with or without 10% glycerol. Electrophoresis was performed at 
300 to 500V for 16 to 20 hours at room temperature or at 4°C. The gel was dried and 
autoradiographed with or without intensifying screen for 3 to 7 hours. 
Table 4. 
Exon 
1 ............. . 
2 ............. . 
3 ............. . 
4 ............. . 
5 ............. . 
6 ............. . 
7 ............. . 
8 ............. . 
3'1 
9 ............. . 
Synthetic Oligonucleotides U sed for Enzymatic 




5' -ACTGGA TCCTCAAGCAACCCTCCAGTT AACC-3,2 
5'-GATGAAGCGAATTCCTCTTCCCCAAAGAGCCTCC-3,1 







5'-ATCGGATCCATCTTGGTGTCTCrl III IACC-3,1 
5'-GATGAAGCGAATTCTTATTTACAACAGTCTCCAG-3,1 




5' -CGTGGA TCCT A TTCACATCCA TTT _3'1 
5' -GATGAAGCGAA TTCGTCAGcrrT AGCCCAGAA TG-3,1 
1. Derived from published exon boundaries (Deeb and Peng, 1989). 
2. Derived from additional sequence information obtained by partial sequencing of 
cosmid cRHL2A (Rata et al., 1990b). 
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DNA Sequencing 
All translated exons for which a mobility shift was identified were sequenced by 
one or more of several methods: 
(1) Direct sequencing from genomic DNA using single-stranded DNA 
template generated by asymmetrical amplification. A segment spanning 
exon 5 of the LPL gene was enzymatically amplified by the polymerase 
chain reaction and the resulting product was purified by spin-dialysis on 
a Centricon 100 column (Amicon, Danvers, MA). An aliquot (1 ).11) was 
used to generate single-stranded DNA by asymmetric amplification (Saiki 
et aI., 1988). Sequencing was performed by application of a standard 
chain-termination protocol (Sanger and Coulson, 1975) with the enzyme 
Sequenase Version 2.0 (U.S. Biochemicals). 
(2) Direct sequencing of double-stranded DNA excised from gels by way 
of a Thermocycling protocol. Bands of altered mobility revealed by 
electrophoresis of amplified DNA fragments spanning exons 1 and 9 of 
human LPL were excised from the dried gel, suspended in 100 ).11 of H20 
and vortexed. After incubation at 37°C for 1 hour, 1 ).11 of each aliquot 
was subjected to enzymatic amplification. The sense- and antisense-
primers included at their 5'-end a sequence complementary to the M13 
universal (5'-TGTAAAACGACGGCCAGT-3') and reverse (5'-CAGGA-
AACAGCT ATGACC-3') priming sites respectively. The reaction mixture 
was subjected to 30 cycles of denaturation at 95°C for 1 minute, 
annealing at 60°C for 1 minute, and extension at 72°C for 1 minute. Each 
amplified product was spin-dialyzed on a Centricon 100 column (Amicon, 
Danvers, MA). 
Direct sequencing of double-stranded DNA was performed on an 
ABI 373A DNA sequencer (Applied Biosystems, Foster City, CA) using 
fluorescent M13 primers, Tag polymerase, and a thermocycling protocol 
supplied by the manufacturer (ABI protocol, 1990). In brief, 12 JlI of a 40 
JlI volume of amplified product were submitted to iterative extensions on 
a DNA thermocycler. Ten cycles were applied, defined by the following 
conditions: denaturation at 95°C for 30 seconds, annealing at 60°C for 1 
second and extension at 70°C for 1 minute. This was followed by 10 
additional cycles of denaturation (95°C for 30 seconds) and extension 
(70°C for 1 minute). The repeated application of several rounds of 
denaturation, reannealing and extension should increase the frequency 
with which termination occurs with incorporation of ddNTP rather than 
dNTP as would occur when template reannealing prevents further 
extension. 
(3) Sequencing of cloned DNA segments. In some instances, DNA 
segments were sequenced after cloning into the M13mp18 vector. These 
segments were generated by enzymatic amplification of genomic DNA 
using 100 pmol of each pair of primers and 2.5 units of Taq polymerase 
in 100 JlI of amplification buffer, with conditions as reported earlier. 
Since the primers used for amplification were augmented with recognition 
sites for the endonucleases BamHI and BcoRI, each amplified fragment 
could be directionally cloned into the M13mp18 vector after restriction 
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enzyme digestion. After bacterial transformation and plating, 6 
independent clones were isolated, and single-stranded DNA was produced 
directly from plaques suspended in distilled water by asymmetric 
enzymatic amplification (Saiki et al., 1988), using the M13 universal and 
reverse primers. Automated analysis of DNA sequence was performed by 
means of an ABI 373A DNA sequencer (Applied Biosystems, Foster City, 
CA). 
Allele-Specific Oligonucleotide Hybridization 
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To verify the presence and test for the zygosity of the mutation identified by 
sequencing, genomic DNA from the subjects analyzed was submitted to enzymatic 
amplification for specific exon fragments. Fifteen Jll (Inth) of the amplification products 
were denatured in 200 J.tl of 0.4 N NaOH/25 mM EDTA solution and 90 J.ll were spotted 
in duplicate onto a nylon membrane (Bio Trace™ RP, Gelman Sciences, Ann Arbor, MI) 
using the BIO-DOT SF apparatus (BIO-RAD, Richmond, CA). After neutralization with 
90 J.lI of 3 M sodium acetate (PH 5.4), DNA was cross-linked by STRA T ALINKER 
(STRATAGENE, La Jolla, CA). Each membrane was hybridized in 50 mM sodium 
phosphate, pH 7.2/0.9 M NaCl/l mM EDTA/0.5% SDS at 42°C with 32P_end labeled 
oligonucleotide probes. Three distinct base substitutions, located in exon 1, 5 and 9 
respectively, were studied by this method. The base substitutions and the oligonucleotide 
sequences used in this study are summarized in Table 5. After hybridization for 2 hours 
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Na citrate, pH 7.0) at 1 to 2°C below the melting temperature computed for each probes, 
and submitted to autoradiography. 
In Vitro Mutagenesis 
Mutagenesis was carried out as described by Kunkel (1985) with some 
modification, using a Muta-Gene M13 in vitro mutagenesis kit, version 2 (BIO-RAD). 
At first, wild type LPL cDNA was released from the clone pLPL35 after digestion with 
SaIl (Wion et al., 1987), and the SaIl sites were converted to EcoRI sites using EcoRI 
linkers. After digestion with EcoRI, this fragment was cloned into the EcoRI site of 
M13mp18 (Figure 5). Oligonucleotide containing the 839 nucleotide mutation (5' -TCGA-
AGCATTGAAATCCAGAAACCAG-3') (exon 5) and 1595 nucleotide mutation (5'-TA-
AGAAGTGAGGCfGAAAC-3') (exon 9) were used as mutagenic primers. 
The template for in vitro mutagenesis was prepared by propagation on the dut, 
ung double mutant bacterium CJ236, leading to the incorporation of Uracil at positions 
normally occupied by Thymine. A complementary strand was synthesized with the T7 
DNA polymerase and closed circles were formed by the T4 DNA ligase. This DNA was 
transformed into E. coli DH5aF', a strain proficient in uracil N-glycosylase activity, 
leading to efficient inactivation of the uracil-containing strands, and thereby yielding the 
non-uracil-containing survivor available for replication. Mutant plaques were selected by 
oligonucleotide hybridization (Figure 6). DNA of M13 phage in the replicative form (RF) 
was isolated by an alkaline lysis minipreparation method (Birnboim, 1983), digested with 
EcoRI and inserted into the EcoRI site of the eukaryotic expression vector pMT2 
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picked for culturing to provide DNA. Proper orientation of insert was determined by 
digestion with the restriction enzyme Pvull. Sequencing analysis of the inserts confirmed 
that either the G to A substitution at position 839 or the C to G substitution at position 
1595 were the only change introduced in the mutant construct. 
Transient Expression in Cultured Mammalian Cells 
COS-l cells were plated at an initial density of 1.0 x 106 per 10 cm dish and 
maintained in 5 ml of Dulbecco's modified Eagle's medium with 10% FCS before 
transfection. They were transfected in triplicate with plasmid DNA (6 Jig/dish), following 
the DEAE-dextran method described by Selden(21) with some modification. One hour after 
DNA addition, chloroquine was added to the medium at a final concentration of 80 JiM. 
After 4 hours of incubation at 37°C, the cells were treated with dimethyl sulfoxide 
(DMSO). The 5 ml of 10% DMSOIPBS was added to each plate and incubated for 2 
minutes at room temperature. After aspirating the DMSO, each plate was then washed 
with 5 ml of Ix PBS. Afterwards, 5 ml of complete medium was added to each plate 
and incubation was carried out at 37°C. Twenty-four hours after transfection, serum-
free, heparin-containing (5 U/ml) medium was substituted and the culture was allowed 
to continue for another 48 hours. Conditioned medium and cells were collected to assay 
LPL activity and immunoreactivity. 
Assay of LPL Mass and Activity 
LPL mass was detennined by a sandwich enzyme-linked immunoadsorbent assay 
using purified bovine LPL as the standard (Iverius and Ostlund-Lindqvist, 1976). LPL 
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activity in conditioned medium or cell lysates was determined by monitoring the 
hydrolysis of triacylglycerols in an emulsion composed of a radiolabeled triolein 
substrate and Intralipid as an emulsifier, as described by Iverius et al. (1985,1986). Both 
assays were performed in the laboratory of Dr P.H. Iverius at the Veterans Affairs 
Hospital, Salt Lake City. 
Affinity Chromatography on Heparin-Sepharose 
Analytical heparin-Sepharose chromatography was performed at O°C using an 
FPLC system (Pharmacia LKB Biotechnology, Inc., Piscataway, NJ ) equipped with a 
FRAC-lOO fraction collector, a HR 5110 column, and a 10 ml Superloop for sample 
loading. The column (2 ml) was packed with heparin-Sepharose CL-6B, prepared as 
described previously (Iverius et al., 1971, 1976), submerged in a cylinder of ice-water 
and equilibrated with 0.15 M NaCl/O.l % (v/v) Triton X-lOOIO.Ol M Na-phosphate buffer 
(pH 7.5). Samples were loaded from a loop at a flow rate of 0.2 ml/min, after which the 
column was washed with 19.5 ml of the equilibration buffer. Elution was performed with 
an 8 mllinear gradient of 0.15 to 1.5M NaCI in 0.1% (v/v) Triton X-lOOIO.Ol M Na-
phosphate buffer (pH 7.5) at a rate 0.05 ml/min. Finally, the column was stripped with 
6 ml of 2 M NaCl in the same buffer at a rate of 0.2 ml/min. Fractions of 0.5 ml were 
collected throughout the procedure in tubes chilled by packing ice into the fraction 
collector carousel. 
RESULTS 
It is hypothetically proposed that molecular variants of the LPL gene can account 
for either LPL deficiency, as documented by lack of LPL activity in the postheparin 
plasma of subjects K2042, or for a subset of more common forms of primary 
hypertriglyceridemia, as observed in the other three subjects under study. Mutational 
events that might affect the gene range from major genomic rearrangements, such as 
large insertions or deletions, to single nucleotide substitutions. Both of these extremes 
have been previously observed in the LPL gene of LPL deficients subjects. 
Probing Total Genomic DNA for Major Rearrangements 
Major rearrangenlents in a gene can be detected by probing genomic DNA after 
digestion with restriction endonucleases. This is of particular relevance here, given the 
report of a common internal duplication in the LPL gene of LPL deficient patients 
(Devlin et aI., 1990). 
Total genomic DNA was digested with the restriction endonucleases PstI and StuI, 
electrophoresed, transferred to nylon membranes, and hybridized to a radiolabelled probe 
containing the entire coding region of the LPL cDNA (pLPL35, a gift from Dick Lawn; 
Wion et aI., 1987). The results are presented in Figure 7. None of the 5 subjects 
exhibited any obvious molecular defect. 
Figure 7. 









Stu I Pst I 
Experimental results from Southern-Blot hybridization. The 
total genomic DNA of 5 study subjects was digested with 
the restriction enzyme Stu I and Pst 1. None of the subjects 
has major gene rearrangement. 
Lane 1: K2039, Lane 2: K2040, Lane 3: K2041 
Lane 4: K2042 , Lane 5: control 
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Detection of Single Nucleotide Substitutions 
Minimal alterations such as nucleotide substitutions eventually require DNA 
sequencing for their characterization. Given the total size of the LPL gene, approximately 
30,000 nucleotides, direct examination of the entire gene is not practical. There are, 
however, a variety of procedures which allow to screen segments of genomic DNA for 
the presence of such variants. 
The approach followed in this work relies on the detection of molecular variants 
through mobility shifts revealed upon electrophoresis of single-stranded DNA under 
nondenaturing conditions. Single-stranded DNA is known to present ordered structures 
in solution, although such structures are much less stable than those adopted by double-
stranded DNA. It has been shown that even a single nucleotide substitution can induce 
a conformational change of single-stranded DNA which can be detected as a mobility 
shift upon electrophoresis under nondenaturing conditions (Kanazawa et aI., 1986). This 
was developed into a method, called by the authors "single-stranded conformation 
polymorphism (SSCP)," for the direct detection of base substitutions in DNA segments 
by Orita et al. (1989). A given DNA segment is amplified by the polymerase reaction, 
labelled during this process through incorporation of a radioactive nucleotide, denatured 
by heat in the presence of formamide, electrophoresed on a polyacrylamide gel under 
nondenaturing conditions, and the latter is subjected to autoradiography. 
This method has been used to examine the nine coding exons and corresponding 
splice junctions of the LPL gene in five study subjects. The primers used for this purpose 
are presented in Table 3. As the conformations adopted are quite sensitive to conditions 
such as pH, ionic strength, temperature and solvent, four distinct electrophoretic 
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conditions were tested. Results obtained are summarized in Figure 8 and Table 6. 
Three distinct mobility shifts were observed. In subject K2039, a mobility shift 
was observed in exon 1 when electrophoresis was performed in the cold room in the 
presence of glycerol. In subject K2041, another mobility shift was observed in exon 9 
under two experimental conditions. Subject K2042 presented a third electrophoretic 
variant in exon 5 of the gene. 
Identification of Molecular Variants by DNA Sequencing 
To identify the sequence variation at the origin of the observed mobility shifts, 
each observed electrophoretic variant was subjected to DNA sequencing. Three distinct 
protocols were applied. 
In the fIrst method, direct sequencing by the chain termination method is 
performed on DNA segments produced by enzymatic amplification from total genomic 
DNA. A drawback of this method, however, is that it may be difficult to identify 
molecular variants present in the heterozygous state. 
The second method, developed in this laboratory by Hata et al. (1990a), exploits 
the electrophoretic separation to purify and sequence an individual allele. Each band 
representing a mobility shift was excised from the gel, resuspended in distilled water, and 
subjected to enzymatic amplification with unique primers extended with universal M13 
direct and reverse primers. After purifIcation of the amplified DNA segment on a spin 
column, an aliquot of double-stranded DNA was sequenced on an automated instrument 
(ABI373A) by the chain termination method using a newly developed thermocycling 
protocol (ABI protocol, 1990). 
Exon 1 Exon5 Exon9 
123450 12345 D 12345 
Figure 8. Experimental results from conformational polymorphism. 
All nine translated exons were examined by this analysis. 
Only sanlple 3 (K 2041) has band displacements in exon 1; 
sample 4 (K 2042) has band mobility differences in exon 5; 
sample 1 (K 2039) has distinct band shifts in exon 9. 
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D: non-denatured, double stranded DNA used as a distance control. 
Table 6. Analysis of Conformational Polymorphism and Results. 
Gly(+) Gly(-) I Gly(+) Gly(-) I Gly(+) Gly(-) I Gly(+) Gly(-) 









9 + + 
Gly (+) -- Polyacrylamide gel with 10% glycerol 
Gly (-) -- Polyacrylamide gel without glycerol 
+ : Mobility shift detected 







The third method relied on subcloning of DNA segments amplified from total 
genomic DNA. Primers were designed to include recognition sequences of restriction 
endonucleases. This allowed to clone the amplified segment into the M13mp18 vector. 
After bacterial transformation, identification of insert-containing plaques, and generation 
of single-stranded DNA by assymetric amplification from such plaques, sequencing was 
perfonned by the chain termination method following a conventional protocol. To allow 
for heterozygosity as well as misincorporation artifacts which may have occurred during 
the amplification steps, several independent clones were sequenced for each target. 
For each segment at the origin of the observed mobility shifts, a single nucleotide 
substitution was observed (Figure 9). The exon 1 variant identified in subject K2039 by 
the second protocol occurred in the noncoding region located upstream of the first 
translated codon. This variant has been identified previously in this laboratory as a 
common polymorphism, and the subject was heterozygous for this mutation. No further 
analysis of this variant was undertaken. 
The exon 9 variant was also identified by application of the second protocol. It 
is a single transversion of a cytosine to a guanine at position 1595, which introduces a 
termination codon at the position nonnally encoding a serine at residue 447 of the mature 
enzyme. The consequence of this mutation is the production of a truncated protein 
lacking two residues at the carboxy terminus of the protein. This variant was previously 
identified in this laboratory (Hata et aI., 1990a) and shown to occur in 30% of Caucasian 
subjects tested in Utah. The electrophoretic pattern revealed in the subject corresponded 
to the heterozygous state. Transient expression of this mutation in cultured mammalian 
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Ser lie Glu lie Glu Lys 
t 
CGAAGCA T T GAAATCCA GAAACCA 
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t 
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Figure 9. Comparison of normal nucleotide sequence with mutant 
sequences found in exons 1, 5, 9, of the LPL gene. Arrows 
point the base change from normal to mutant. Asterisks 
indicate the stop codon. 
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Individual K2042, who presented typical LPL deficiency, was the offspring of a 
consanguineous marriage. Furthennore, the electrophoretic pattern exhibited by this 
subject, with an apparent absence of bands of characteristic wild type mobilities, 
suggested that he might be homozygous for a mutation in exon 5 of the LPL gene. 
Consequently, direct sequencing was fIrst applied. A guanine-to-adenine transition at 
nucleotide position 839 was observed. This leads to a missense mutation with the 
substitution of glutamic acid for glycine at residue 195 of the mature enzyme. The 
presence of this mutation was confIrmed when two clones were sequenced by the third 
method: both clones contained this mutation. Hybridization of total genomic DNA of the 
patient with synthetic oligonucleotides specific for wild type and mutant sequences at this 
position established that the patient was homozygous for this mutation (Figure 10). 
The 839A Mutation Encodes a Functionally Inactive Enzyme 
The functional significance of the amino acid substitution observed in subject 
K2042 cannot be inferred from the sequence alone. Therefore, the mutation was 
reproduced in vitro, expressed in cultured cells, and cell lysates and conditioned media 
were assayed for several criteria of LPL. 
The experimental protocols used were presented in the previous section, and 
therefore they are only briefly outlined here. As LPL is a glycoprotein, a mammalian 
expression system was used. Mutagenesis was performed by second-strand synthesis on 
a wild type template initiated by a mutagenic synthetic oligonucleotide which differed 
from the wild type sequence only with respect to the observed mutation. The wild type 
strand had been prepared in a deficient bacterial strain, which resulted in the 
Figure 10. 
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WILD TYPE I I. 
MUTANT I 
Experimental results from allele-specific oligonucleotide 
hybridization. Allele-specific oligonucleotide hybridization 
after enzymatic amplification of a segment of exon 5 from 
the LPL gene. Column 1 corresponds to sample 4 (K 2042) 
(homozygous for this mutation). Columns 2 and 3 are 
normal controls (homozygous for wild type). 
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incorporation of uracil instead of thymine at a number of positions. As a consequence, 
when double-stranded heteroduplexes generated at the mutagenic step were propagated 
in a wild type bacterial strain, the uracil-containing strand was hydrolyzed, yielding a 
high proportion of plaques containing only mutant phages. Several plaques were selected 
and the presence of the desired mutation was confirmed by DNA sequencing. The LPL 
insert of one such phage was released and transferred into the expression vector pMT2, 
where the LPL gene is placed under the control of the major promoter of Adenovirus. 
After transfection of cultured monkey kidney cells (COS-l cells), cell lysates and 
conditioned media were collected and analyzed by Dr P.H. Iv erius, at the Veterans 
Affairs Hospital. A positive control was provided by parallel transfection with a vector 
containing the wild type sequence. 
The results of such assays are presented in Table 7. Immunoreactive LPL material 
was detected with a monoclonal antibody for human LPL in celllysates and conditioned 
media obtained after transfections with both wild-type and mutant sequences. However, 
while transfection with the wild-type sequence led to the recovery of active enzyme in 
both celllysates and conditioned medium, no such activity could be detected in cells and 
media of transfection experiments performed with the vector containing the 839A 
mutation. Preliminary results indicates that the immunoreactive material detected in cells 
transfected with pMTI-LPL839A has slightly reduced affinity for heparin compared to 
wild-type enzyme when analyzed by heparin-Sepharose chromatography. 
In conclusion, data obtained demonstrate that the 839A mutation leads to the 
production of functionally inactive enzyme, which accounts for the enzymatic deficiency 
noted in subject K2042. 
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Four hypertriglyceridemic subjects for the possible presence of mutations in the 
LPL gene have been examined. No major genomic rearrangement was revealed when 
total genomic DNA digested with selected enzymes was resolved by electrophoresis, 
transferred to nylon membranes, and hybridized to a cDNA probe spanning the entire 
coding region of the gene. Subsequently, genomic segments of DNA enzymatically 
amplified by the polymerase reaction were submitted to electrophoresis on 
polyacrylamide gels in an attempt to detect mobility shifts induced by nucleotide 
substitutions. Three distinct electrophoretic variants were detected, and the sequences of 
the corresponding DNA segments were determined. 
A nucleotide substitution identified in ex on 1 of the gene occurs upstream from 
the translated region. This variant was previously identified in a number of other subjects 
in this laboratory, and it is likely to represent a common polymorphism. Calculations 
based on estimates of nucleotide substitution and the neutral theory of molecular 
evolution predict that one such polymorphism is expected for every 100 to a few 
hundreds nucleotides in regions devoid of functional significance. Without evidence for 
any function of the sequence involved, it is reasonable to assume that this common 
polymorphism is without biochemical significance. 
Another subject presented a nucleotide substitution in exon 9 of the gene which 
introduces a premature stop codon. As a consequence, this molecular variant encodes a 
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truncated protein lacking the last two amino acids normally observed at the carboxy-
terminal end of the protein. This variant had also been identified previously in this 
laboratory, occurring among 30% of Utah subjects of Northern European descent (Hata 
et aI., 1990a). The mutation was reproduced in vitro and expressed in cultured 
mammalian cells. The truncated protein was similar to the wild type enzyme with respect 
to the properties examined: enzymatic activity towards a triolein lipid emulsion, 
immunoreactivity with a monoclonal antibody, and affinity for heparin when analyzed 
by heparin-sepharose chromatography. 
The third variant identified corresponded to a nucleotide substitution in exon 5 
of the LPL gene, leading to a single amino acid substitution at position 195 of the mature 
enzyme, with the presence of glutamic acid instead of glycine. This mutation was present 
in the homozygous state in the patient. When expressed in cultured cells, this sequence 
yielded immunoreactive but inactive LPL. Preliminary data indicated that affinity for 
heparin, as examined by chromatography on an heparin-Superose column, was not 
impaired in a major way. This patient presented classical LPL deficiency, with no 
significant LPL activity in post heparin plasma, and he was the offspring of a 
consanguineous marriage. Therefore, it can be concluded that the mutation identified is 
responsible for this enzyme deficiency and its accompanying clinical manifestations. 
While the molecular defect responsible for LPL deficiency observed in patient 
K2042 has been identified, the hypothesis that mutations in the LPL gene may account 
for the more common types of hypertriglyceridemia observed in the other three subjects 
cannot be confirmed, despite a report documenting the delayed expression of 
hypertriglyceridemia in individual pedigree members heterozygous for a single amino 
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acid difference in the LPL gene, the substitution of glutamic acid for glycine at residue 
188 (Wilson et aI., 1990). There are several possible interpretations for this observation: 
(1) Expression of hypertriglyceridemia in heterozygotes for LPL 
deficiency requires saturation of the reduced clearance rate of such 
subjects by extraneous factors that were present in the pedigree studied by 
Wilson et al. (1990) but absent in present series of cases of French origin. 
These might be diet, habitus, or other genetic determinants as yet 
unidentified. Another possible interpretation is that not all mutations of 
LPL lead to the latent defect associated to the mutation noted in that 
pedigree. 
(2) Some mutations present in the DNA segments screened may 
not have been detected by present electrophoretic screening. To be 
identified, a nucleotide substitution must induce a conformational change 
in single-stranded DNA under the experimental conditions used for this 
screening. When a variety of known susbtitutions were tested by this 
method, it was found that about 80% could be detected by this method 
when four distinct conditions (room temperature or cold room and 
glycerol or no glycerol) were used (Rata et aI., 1990a). When eight known 
variants of the LPL gene were tested in this laboratory, all but one could 
be detected under at least one of the four experimental conditions used 
here. 
(3) Mutations may occur in parts of the gene which were not 
examined in present screening. Analysis of total genomic DNA by 
Southern blotting is of limited resolution, and only exons and 
corresponding intron-exon boundaries were screened for conformational 
polymorphism. The gene spans over 30 kilobases of genomic DNA, and 
it is reasonable to assume that various noncoding regions may be affected 
by mutations of functional significance, whether small insertions or 
deletions or nucleotide substitutions. 
For smaller targets such as the alpha-globin and beta-globin genes, 
which have been subjected to intense examination in light of their modest 
sizes (1 and 2 kilobases respectively) and their implication in 
hemoglobinopathies, a vast array of mutations affecting domains other 
than exons and splice junctions have been identified (Weatherall et al., 
1989), such as mutations affecting the rate of transcription or the stability 
of mRNA, mutations activating cryptic splice sites in exons or in introns, 
or mutations at polyadenylation sites. 
(4) Other genes may be involved in the etiology of 
hypertriglyceridemia. These could be regulatory proteins affecting LPL 
gene expression, or they could be other genes affecting triglyceride 
metabolism. 
(5) Various hormonal and environmental determinants can account 
for hypertriglyceridemia in the absence of a molecular defect in lipid and 
lipoprotein metabolism, and these are of more common occurrence than 
heterozygosity for LPL defects. 
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Experimental data obtained indicate that the mutation noted in subject 4 (K2042) leads 
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to the production of inactive enzyme in present in vitro heterologous expression system. 
Although LPL contains multiple functional domains which, if altered, could conceivably 
lead to functional deficiency, it is likely that the mutation at residue 195 directly impairs 
the catalytic activity of the enzyme, at least with respect to lipid emulsions. Figure 4 
shows the sequence alignment of human pancreatic lipase and lipoprotein lipase for that 
region of greatest homology. The recent detennination of the three-dimensional structure 
of human pancreatic lipase by Winkler et al. (1990) has provided clear evidence that this 
segment of the protein includes the catalytic domain. This domain includes the catalytic 
triad Ser-Asp-His found in serine proteases. However, the active serine is flanked by 
hydrophobic residues and the elements of the catalytic triad are embedded into a deep 
pocket, a structure which may account for the specificity of the enzyme for liposoluble 
substrates and its activity at lipid-water interfaces. The homology between LPL and 
pancreatic lipase is greatest in the vicinity of the three elements of the catalytic triad, and 
therefore it is reasonable to assume that this region of LPL also constitutes its catalytic 
domain. Residue 195 occurs in this region, and therefore it can be proposed that the 
mutation noted in subject 4, although preserving the active site, affects the catalytic 
domain of the enzyme. The precise mechanism by which loss of function occurs as a 
result remains to be determined. 
CONCLUSION 
Present experimental data support the conclusion that a mutation leading to a 
single amino acid substitution at residue 195 of the mature LPL enzyme, with glutamic 
acid instead of glycine, results in the production of inactive enzyme in subject K2042 
and accounts for this subject's chylomicronemia syndrome. Honlology between human 
lipoprotein lipase and pancreatic lipase and the reported structure of the latter suggests 
that this nlutation occurs within the catalytic site of the molecule. The etiology of the 
hypertriglyceridemia noted in three other subjects remains unresolved, as no evidence of 
the functional significance of two other mutations has been found. 
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